|Tested species reactivity||Bovine, Human, Mouse, Rat|
|Published species reactivity||Rat, Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG2a, kappa|
|Immunogen||Recombinant rat c-erbB-3/HER-3 oncoprotein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Western Blot (WB)||4 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 10 publications below|
|Immunohistochemistry (IHC)||See 2 publications below|
|Immunocytochemistry (ICC)||See 4 publications below|
|Immunofluorescence (IF)||See 1 publications below|
|Immunoprecipitation (IP)||See 3 publications below|
|Blocking Assay (BLOCK)||See 1 publications below|
MA5-12675 targets HER-3 in WB applications and shows reactivity with Bovine, Human, mouse, and Rat samples.
The MA5-12675 immunogen is recombinant rat c-erbB-3/HER-3 oncoprotein.
c-erbB-3/HER-3 is the third member of the type I family of growth factor receptors. It binds to ligands in the heregulin family. c-erbB-3 is over-expressed in a variety of tumors including breast, stomach, pancreas, and colon. Heregulin and EGF stimulate tyrosine phosphorylation of c-erbB-3 to different extents.
IP-MS enrichment of ERBB3 (LFQ intensity): ERBB3 was enriched 525-fold from MCF7 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ERBB3 antibody (Part No. MA5-12675). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.
MA5-12675 was used in immunoprecipitation and western blot to study mechanism of resistance to the FGFR inhibitor BGJ398 and the FGFR inhibitor ponatinib
|Wang J,Mikse O,Liao RG,Li Y,Tan L,Janne PA,Gray NS,Wong KK,Hammerman PS||Oncogene (34:2167)||2015|
|Not Applicable||Not Cited||
MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion.
MA5-12675 was used in western blot to discuss targeting MiR-221/-222 to treat breast cancer
|Falkenberg N,Anastasov N,Rappl K,Braselmann H,Auer G,Walch A,Huber M,Höfig I,Schmitt M,Höfler H,Atkinson MJ,Aubele M||British journal of cancer (109:2714)||2013|
Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines.
MA5-12675 was used in western blot to study the value of HER3 expression and markers of epithelial-mesenchymal transition in predicting sensitivity of breast and pancreatic cancer cell lines to elisidepsin
|Teixidó C,Marés R,Aracil M,Ramón y Cajal S,Hernández-Losa J||PloS one (8:null)||2013|
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs.
MA5-12675 was used in western blot to investigate the role of EGFR signaling in the effects of ERBB2-targeting drugs
|Henjes F,Bender C,von der Heyde S,Braun L,Mannsperger HA,Schmidt C,Wiemann S,Hasmann M,Aulmann S,Beissbarth T,Korf U||Oncogenesis (1:null)||2012|
EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
MA5-12675 was used in western blot to study the effect of
|Dua R,Zhang J,Nhonthachit P,Penuel E,Petropoulos C,Parry G||Breast cancer research and treatment (122:685)||2010|
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
MA5-12675 was used in western blot to identify mechanisms of tumor growth inhibition in ovarian cancer
|Sheng Q,Liu X,Fleming E,Yuan K,Piao H,Chen J,Moustafa Z,Thomas RK,Greulich H,Schinzel A,Zaghlul S,Batt D,Ettenberg S,Meyerson M,Schoeberl B,Kung AL,Hahn WC,Drapkin R,Livingston DM,Liu JF||Cancer cell (17:298)||2010|
All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.
MA5-12675 was used in western blot to study the dimerization of epidermal growth factor receptors prior to epidermal growth factor binding in plasma membrane
|Tao RH,Maruyama IN||Journal of cell science (121:3207)||2008|
Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
MA5-12675 was used in western blot to study the treatment of malignant pleural mesothelioma by targeting multiple signaling pathways
|Mukohara T,Civiello G,Johnson BE,Janne PA||Oncology (68:500)||2005|
The neuregulin GGF2 attenuates free radical release from activated microglial cells.
MA5-12675 was used in western blot to investigate the protective effect of neuregulin GGF2 against free radical release from activated microglial cells
|Dimayuga FO,Ding Q,Keller JN,Marchionni MA,Seroogy KB,Bruce-Keller AJ||Journal of neuroimmunology (136:67)||2003|
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
MA5-12675 was used in western blot to study the inhibition of HER2-driven signaling and growth suppression of HER2-overexpressing tumor cells by Iressa
|Moasser MM,Basso A,Averbuch SD,Rosen N||Cancer research (61:7184)||2001|
Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
MA5-12675 was used in immunohistochemistry to identify the effects of the epidermal growth factor receptor 2 and the protein tyrosine kinase 6 in relation to breast cancer treatment
|Falkenberg N,Anastasov N,Höfig I,Bashkueva K,Lindner K,Höfler H,Rosemann M,Aubele M||Molecular oncology (9:282)||2015|
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
MA5-12675 was used in immunohistochemistry to study the mechanism for the resistance of MET oncogene-addicted gastric cancer cells against MET inhibitors
|Bachleitner-Hofmann T,Sun MY,Chen CT,Tang L,Song L,Zeng Z,Shah M,Christensen JG,Rosen N,Solit DB,Weiser MR||Molecular cancer therapeutics (7:3499)||2008|
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
MA5-12675 was used in immunocytochemistry, immunohistochemistry, and western blot to study the value of the expression and dimerization patterns of EGFR, HER2 and HER3 in esophageal cancer histotypes for guiding targeted anti-EGFR and -HER2 therapy
|Fichter CD,Timme S,Braun JA,Gudernatsch V,Schöpflin A,Bogatyreva L,Geddert H,Faller G,Klimstra D,Tang L,Hauschke D,Werner M,Lassmann S||International journal of cancer (135:1517)||2014|
Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
MA5-12675 was used in immunocytochemistry to study the effect of spontaneous and pronase-induced HER2 truncation on the trastuzumab binding capacity of breast cancer tissues and cell lines
|Recupero D,Daniele L,Marchiò C,Molinaro L,Castellano I,Cassoni P,Righi A,Montemurro F,Sismondi P,Biglia N,Viale G,Risio M,Sapino A||The Journal of pathology (229:390)||2013|
ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells.
MA5-12675 was used in immunocytochemistry and western blot to study the role of ErbB4 in regulating fetal surfactant phospholipid synthesis in primary fetal rat type II cells
|Zscheppang K,Liu W,Volpe MV,Nielsen HC,Dammann CE||American journal of physiology. Lung cellular and molecular physiology (293:L429)||2007|
ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells.
MA5-12675 was used in immunocytochemistry to study erbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells
|Zscheppang K,Korenbaum E,Bueter W,Ramadurai SM,Nielsen HC,Dammann CE||Pediatric pulmonology (41:1205)||2006|
HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
MA5-12675 was used in proximity ligation assay to research p21 expression and HER2/HER3 heterodimers and prediction of adjuvant trastuzumab response in HER2+ breast cancer
|Green AR,Barros FF,Abdel-Fatah TM,Moseley P,Nolan CC,Durham AC,Rakha EA,Chan S,Ellis IO||Breast cancer research and treatment (145:33)||2014|
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
MA5-12675 was used in immunoprecipitation to study the switch from ER/HER to HER/c-Src signaling as T47D breast cancer cells acquire fulvestrant resistance
|Kirkegaard T,Hansen SK,Larsen SL,Reiter BE,Sørensen BS,Lykkesfeldt AE||Cancer letters (344:90)||2014|
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
MA5-12675 was used in immunoprecipitation and western blot to study the role of HER-2 signaling in the regulation of biological networks associated with cell transformation
|Bollig-Fischer A,Dziubinski M,Boyer A,Haddad R,Giroux CN,Ethier SP||Cancer research (70:7862)||2010|
Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
MA5-12675 was used in immunoprecipitation to investigate the effect of an anti-EGFR antibody on non-small cell lung cancer cell lines
|Maegawa M,Takeuchi K,Funakoshi E,Kawasaki K,Nishio K,Shimizu N,Ito F||Molecular cancer research : MCR (5:393)||2007|
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.
MA5-12675 was used in blocking or activating experiment to study prognostic value of HER2:HER2 and HER2:HER3 protein-protein interactions in breast cancer
|Spears M,Taylor KJ,Munro AF,Cunningham CA,Mallon EA,Twelves CJ,Cameron DA,Thomas J,Bartlett JM||Breast cancer research and treatment (132:463)||2012|